April/May #179 : Is the World Prepped for PrEP? - by Laura Whitehorn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents


Meet the Parents

HIV Care on the Front Line

From the Editor

How to Survive a Plague


Letters- April/May 2012


Battling Back

What You Need to Know

Happily Ever After: Same-Sex Marriage Protects Gay Health

Red Cross Sees Red After Millions in Fines

Advocates Seek an End to HIV Criminalization

July May Be the First Annual National HIV Awareness Month

Tune In: HIV/AIDS Makes a Star-Studded Comeback

We Hear You

AIDS on the Political Stage

POZ Survey Says

Your Opinions on AIDS 2012

What Matters to You

Legalizing Syringe Exchange

Treatment News

Is the World Prepped for PrEP?

Mixing HIV and Anti-Seizure Drugs Safely

A Spinal Remedy for HIV-Related Neuropathy?

Depression Affects More HIV-Positive Women Than Men

HIV Treatment as Prevention

An Aspirin a Day Might Keep Cervical Cancer at Bay

Comfort Zone

Spring Cleaning

POZ Heroes

Chicken Soup for the Soul

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

April / May 2012

Is the World Prepped for PrEP?

by Laura Whitehorn

PrEPOral PrEP, or pre-exposure prophylaxis, is when HIV-negative people take a daily dose of HIV meds to reduce their chance of contracting HIV sexually. PrEP has been studied in a number of trials, one of which showed efficacy rates ranging from 44 percent to more than 90 percent in men who have sex with men (MSM; the gap hinges on adherence rates). The biggest clinical trial testing PrEP in women was FEM-PrEP. The study was discontinued last April due to efficacy concerns (poor adherence was recently cited as the cause). 

Gilead Sciences, manufacturer of Truvada (emtricitabine and tenofovir), has applied for FDA approval of Truvada as PrEP in HIV-negative men—and women. The FDA’s answer is expected by July.

A new MSM PrEP study is under way in France (for info, Google “IPERGAY”), and another is planned for Montreal. Before the FDA greenlights PrEP, we would like to see new studies that investigate adherence. And we’d still like to see more trials for the ladies—especially in the United States where none have been done.

Search: France, PrEP, pre-exposure prophylaxis, FEM-PrEP, men who have sex with men, MSM, clinical trial, Gilead Sciences, Truvada, FDA, IPERGAY

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.